이 페이지의 번역은 실험적이며 개발 중입니다. 여러분의 환영합니다!

Biodesix 관리

관리 기준 확인 3/4

Biodesix's CEO는 Scott Hutton, Jan2020 에 임명되었습니다 의 임기는 4.42 년입니다. 총 연간 보상은 $ 2.29M, 22.5% 로 구성됩니다. 22.5% 급여 및 77.5% 보너스(회사 주식 및 옵션 포함). 는 $ 820.93K 가치에 해당하는 회사 주식의 0.35% 직접 소유합니다. 820.93K. 경영진과 이사회의 평균 재임 기간은 각각 4.3 년과 4.4 년입니다.

주요 정보

Scott Hutton

최고 경영자

US$2.3m

총 보상

CEO 급여 비율	22.5%
CEO 임기	4.5yrs
CEO 소유권	0.4%
경영진 평균 재임 기간	4.4yrs
이사회 평균 재임 기간	4.5yrs

최근 관리 업데이트

Recent updates

Biodesix, Inc.'s (NASDAQ:BDSX) Popularity With Investors Is Clear

Jun 12

With A 25% Price Drop For Biodesix, Inc. (NASDAQ:BDSX) You'll Still Get What You Pay For

Mar 03

Biodesix, Inc.'s (NASDAQ:BDSX) P/S Is Still On The Mark Following 28% Share Price Bounce

Jan 04

Need To Know: Analysts Just Made A Substantial Cut To Their Biodesix, Inc. (NASDAQ:BDSX) Estimates

Nov 25

Bearing In On Biodesix

Sep 13

Time To Worry? Analysts Are Downgrading Their Biodesix, Inc. (NASDAQ:BDSX) Outlook

Aug 16

Biodesix: Continued Concerns After The Boom-Bust Cycle

Jul 14

CEO 보상 분석

Scott Hutton 의 보수는 Biodesix 의 수익과 비교하여 어떻게 변경되었나요?
날짜	총 보상	급여	회사 수익
Mar 31 2024	n/a	n/a	-US$47m
Dec 31 2023	US$2m	US$515k	-US$52m
Sep 30 2023	n/a	n/a	-US$63m
Jun 30 2023	n/a	n/a	-US$66m
Mar 31 2023	n/a	n/a	-US$69m
Dec 31 2022	US$3m	US$515k	-US$65m
Sep 30 2022	n/a	n/a	-US$58m
Jun 30 2022	n/a	n/a	-US$56m
Mar 31 2022	n/a	n/a	-US$52m
Dec 31 2021	US$5m	US$490k	-US$43m
Sep 30 2021	n/a	n/a	-US$34m
Jun 30 2021	n/a	n/a	-US$32m
Mar 31 2021	n/a	n/a	-US$29m
Dec 31 2020	US$2m	US$364k	-US$31m
Sep 30 2020	n/a	n/a	-US$33m
Jun 30 2020	n/a	n/a	-US$34m
Mar 31 2020	n/a	n/a	-US$33m
Dec 31 2019	US$337k	US$298k	-US$31m

보상 대 시장: Scott 의 총 보상 ($USD 2.29M )은 US 시장( $USD 1.62M ).

보상과 수익: Scott 의 보상은 지난 한 해 동안 회사 성과와 일치했습니다.

CEO

Scott Hutton (52 yo)

4.5yrs

테뉴어

US$2,290,546

보상

Mr. Scott Hutton serves as President, Chief Executive Officer and Director at Biodesix, Inc. since January 1, 2020. He served as Chief Operating Officer at Biodesix, Inc. since March 2018 until December 20...

리더십 팀

이름	위치	테뉴어	보상	소유권
Scott Hutton	President	4.5yrs	US$2.29m	0.35% $ 780.1k
Robin Cowie	CFO, Secretary & Treasurer	7.3yrs	US$844.37k	0.13% $ 289.1k
Kieran O'Kane	Chief Commercial Officer	6.4yrs	US$672.62k	0.061% $ 135.6k
Heinrich Röder	Founder & CTO	no data	데이터 없음	데이터 없음
Jessica Olbricht	Senior Director of Human Resources	less than a year	데이터 없음	데이터 없음
Gary Pestano	Chief Development Officer	5.8yrs	데이터 없음	0.086% $ 191.4k
Bobbi Coffin	Chief Growth Officer	4.3yrs	데이터 없음	데이터 없음
James Jett	Co-Chief Medical Officer	no data	데이터 없음	데이터 없음
Steven Springmeyer	Co-Chief Medical Officer	4.2yrs	데이터 없음	데이터 없음
Christopher Vazquez	VP & Controller	3.4yrs	데이터 없음	0.0074% $ 16.5k

4.4yrs

평균 재임 기간

49.5yo

평균 연령

경험이 풍부한 관리: BDSX 의 관리팀은 경험 ( 4.3 년 평균 재직 기간)으로 간주됩니다.

이사회 구성원

이름	위치	테뉴어	보상	소유권
Scott Hutton	President	4.5yrs	US$2.29m	0.35% $ 780.1k
John Patience	Independent Chairman	16.1yrs	US$187.58k	5.03% $ 11.2m
Jack Schuler	Independent Director	16.1yrs	US$187.58k	21.22% $ 47.1m
Hany Massarany	Independent Director	4yrs	US$201.47k	0.22% $ 481.4k
Lair Kennedy	Independent Director	1.5yrs	US$465.10k	17.47% $ 38.8m
Paul A. Bunn	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Matthew Strobeck	Independent Director	12.5yrs	US$196.84k	2.11% $ 4.7m
John Kayyem	Independent Director	2.6yrs	US$187.58k	0.25% $ 547.0k
David Carbone	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Craig Whitehouse	Member of Scientific Advisory Board	no data	데이터 없음	데이터 없음
Jean Franchi	Independent Director	4.3yrs	US$206.10k	0.056% $ 125.1k
Charles Watts	Independent Director	5yrs	US$187.58k	0.24% $ 533.4k

4.5yrs

평균 재임 기간

63yo

평균 연령

경험이 풍부한 이사회: BDSX 의 이사회는 경험(평균 재직 기간 4.4 년)으로 간주됩니다.

Biodesix 관리

관리 기준 확인 3/4

주요 정보

최근 관리 업데이트

Biodesix, Inc., Annual General Meeting, May 21, 2024

President notifies of intention to sell stock

Independent Director recently bought US$217k worth of stock

Biodesix, Inc. Announces Resignation of Ryan Siurek as Chief Accounting Officer, Effective July 3, 2023

Independent Director recently bought US$65k worth of stock

Independent Director recently bought US$125k worth of stock

Recent updates

Biodesix, Inc.'s (NASDAQ:BDSX) Popularity With Investors Is Clear

New major risk - Shareholder dilution

Biodesix, Inc. to Present New Data on the Nodify XL2 Test at ATS 2024 Annual Meeting

First quarter 2024 earnings: EPS and revenues exceed analyst expectations

Biodesix, Inc. to Report Q1, 2024 Results on May 08, 2024

Biodesix, Inc., Annual General Meeting, May 21, 2024

Biodesix, Inc. announced that it expects to receive $34.999422 million in funding

Biodesix, Inc. has completed a Follow-on Equity Offering in the amount of $20.000607 million.

With A 25% Price Drop For Biodesix, Inc. (NASDAQ:BDSX) You'll Still Get What You Pay For

Full year 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Biodesix, Inc. Provides Revenue Guidance for the Year 2024

Biodesix, Inc. to Report Q4, 2023 Results on Mar 01, 2024

President notifies of intention to sell stock

Biodesix, Inc.'s (NASDAQ:BDSX) P/S Is Still On The Mark Following 28% Share Price Bounce

Biodesix, Inc. Enhances Access to Nodify Lung Testing with Launch of New Blood Draw Method

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Biodesix, Inc. Provides Revenue Guidance for the Year 2023

Biodesix, Inc. to Report Q3, 2023 Results on Nov 07, 2023

New major risk - Share price stability

Biodesix, Inc. Announces Two Presentations on Lung Cancer Treatment Guidance Tests at the IASLC 2023 World Lung Conference on Lung Cancer

Independent Director recently bought US$217k worth of stock

Biodesix, Inc. Announces Presentation of New Nodify XL2(R) Data at AABIP Conference Highlighting Increased Proportion of Biopsies Diagnosing Cancer

Consensus EPS estimates upgraded to US$0.68 loss

New major risk - Negative shareholders equity

Second quarter 2023 earnings: EPS and revenues exceed analyst expectations

Biodesix, Inc. to Report Q2, 2023 Results on Aug 07, 2023

It's Down 28% But Biodesix, Inc. (NASDAQ:BDSX) Could Be Riskier Than It Looks

Biodesix, Inc. Announces Publication of the ORACLE Clinical Utility Study with the Primary Endpoint Demonstrating That the Nodify XL2 Test Reduced Unnecessary Invasive Procedures on Benign Lung Nodules

Biodesix, Inc. Receives Advanced Diagnostic Laboratory Test Status for its Nodify CDT® Test by the Center for Medicare and Medicaid Services

Biodesix Completes Enrollment of Insight Study Assessing Clinical Utility of the Veristrat®? Blood-Based Host Immune Classifier

Biodesix, Inc. Announces Resignation of Ryan Siurek as Chief Accounting Officer, Effective July 3, 2023

Independent Director recently bought US$65k worth of stock

Biodesix, Inc. Announces New Clinical Utility Evidence for the Nodify XL2 Nodule Risk Assessment Test to Be Presented at ATS 2023 International Conference

First quarter 2023 earnings: Revenues exceed analysts expectations while EPS lags behind

Biodesix, Inc. Reaffirms Revenue Guidance for the Year 2023

Full year 2022 earnings: EPS and revenues miss analyst expectations

Independent Director recently bought US$125k worth of stock

Biodesix Announces First Four Private Payer Coverage Policies for the Nodify Xl2® Test

Biodesix Announces First Four Private Payer Coverage Policies for the Nodify Xl2® Test

Biodesix, Inc. Announces Appointment of Lawrence (Lair) T. Kennedy, Jr. to Board of Directors and Audit Committee of the Board, Effective January 3, 2023

Independent Director recently bought US$148k worth of stock

Biodesix, Inc. has completed a Follow-on Equity Offering in the amount of $30 million.

Price target decreased to US$5.00

Biodesix, Inc. Presents New Data from the Insight Study At the 2022 Society for Immunotherapy of Cancer 37Th Annual Meeting

Third quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Biodesix, Inc. Provides Earnings Guidance for the Year 2022

Biodesix, Inc. to Report Q3, 2022 Results on Nov 03, 2022

A Second Look At Biodesix

Biodesix, Inc. Provides Revenue Guidance for the Third Quarter 2022

Biodesix expects Q3 revenue above the consensus

Second quarter 2022 earnings: EPS and revenues exceed analyst expectations

Biodesix, Inc. Reaffirms Revenue Guidance for the Year 2022

Biodesix GAAP EPS of -$0.40 beats by $0.07, revenue of $10.95M beats by $2.12M

Biodesix, Inc. to Report Q2, 2022 Results on Aug 04, 2022

Biodesix, Inc.(NasdaqGM:BDSX) dropped from Russell 2000 Growth Index

Biodesix, Inc. Obtains Medicare Coverage for the Nodify CDT Lung Nodule Test

Biodesix: Bad Diagnosis

Consensus forecasts updated

First quarter 2022 earnings: Revenues exceed analysts expectations while EPS lags behind

Biodesix, Inc. Provides Revenue Guidance for the Year 2022

Price target decreased to US$9.00

High number of new directors

Consensus forecasts updated

Independent Director recently bought US$5.0m worth of stock

Biodesix, Inc., Annual General Meeting, May 24, 2022

Consensus revenue estimates increase by 10%

Full year 2021 earnings: Revenues and EPS in line with analyst expectations

Analysts' Revenue Estimates For Biodesix, Inc. (NASDAQ:BDSX) Are Surging Higher

Biodesix, Inc. Announces Impactful Clinical Data on the Primary Immune Response Test at IASLC 2022 Therapies of Lung Cancer Meeting